 Hello, everybody. Welcome back to Investor Intel. I'm Peter Clausi and we're revisiting X-Fight of Therapeutics today who we last talked to in early March. Joining us is Hugh Rogers, CEO and a director. Hi, Peter. Thanks for having me. Nice to see you again. A lot's going on in the company since the first week of March. I'm scrolling through the press releases. It seems you have a major announcement every week. To your eye, what is the most important announcement you've made? So, mid-March, we announced commercial approval, so CE-IVD mark for our rapid point-of-care COVID-19 test. So that was a major milestone. The company went from basically invention to commercial approval in less than 12 months. So that's pretty exciting. Yeah, in the kind of unheard of in the biotech world and now into launching sales. So we've had some exciting news, some partnerships developing in Israel. We've had some samples there for regulatory approval. We've just very recently launched a pilot project with a partner pharmacy in Germany. This is developing mobile protocols for testing, so everything from lab on wheels to satellite pop-up labs. So that really is kicking off our entrance into the German market, which is pretty exciting. Now, the last time we talked, we made a joke about sometimes it's better to be lucky than good, because a lot of your scientific team came from the infectious disease side. That's right. So we've got a few different verticals. We're in the diagnostic space. We're in the drug formulation space. We're also in the sort of emerging API. So we have cannabinoid and psychedelic drug formulations going on, as well as API production. But our core team, our drug formulation experts, actually, if we dig deep enough into the resumes, we're infectious disease experts. And as we built our team in Germany just by chance, the people that ended up joining the team were also infectious disease experts. So it was a pretty seamless transition into the diagnostic space. Right. I see recently you delivered COVID-19 tests to Israel. You're distributing them in Germany and you hired a new COO for your German subsidiary. That's right. So the big one in terms of personnel and the team is building rapidly. Wolfgang Probst, the former managing director of XP Diagnostics is now our COO. A little bit further down in that email, you'll see Manfred Buchberger. So Manfred Buchberger was a former head of sales and then CEO for a major European Diagnostics company. He helped build that company from about 2 million euro a year in revenue to 600 million euro a year in revenue. And he is leading our push into the European market. So he's a superstar and we're very lucky to have him. Now it's going to be exciting news, but all of this takes money. What's your treasury looking like? Yeah, we've got a couple of billion dollars in the bank. I mean, we always have a few million dollars in the bank generally. We exercise a lot of warrants day to day from our original shareholders in a fairly methodical manner, which has funded us largely going forward. As we grow the business and really launch sales in Europe, I think we'll look to probably secure some sort of a revolving line of credit to fund inventory on the manufacturing side, which would be our largest line item going forward. You probably get some help from the BDC. Likely the German government. So certainly grants and potential zero interest loans for that sort of thing. Not unlike in North America, there's a lot of government funding for these types of projects. So I'm looking at a stock chart that's a little choppy. It's been up, it's been down, it's been up. You're trading around $283 today, 70 million shares out roughly. Approximately 70 million, just under. Yeah, I mean, it's been a pretty volatile stock overall. I think we play in some pretty aggressive industries and everything from vaccine announcements to third, fourth, fifth waves. So we bounce around a fair bit. But we're transitioning and this has been really a transformational year for the company is as we bring products to market, we're transitioning into revenue and sort of more conventional metrics and really looking forward to some strong announcements over the next 60 to 90 days. Okay. Now, what I really want to ask is where do you think we'll be in a year, but I'm not going to put you offside for looking financial information. But it looks like you're going to have a strong year of revenue at least based on the press releases that have been out already. Yeah, that's right. So we're really excited about our diagnostics business. We also have a number of milestones on the drug formulation side, news pending on our Q1 routine transdermal patch study. We also have a CBD sublingual study that will be launching very soon and Q2 followed by one human study each quarter and Q3, Q4. So lots going on with the company. We've got psychedelic API production projects in Germany and in Canada. So we have this incubator accelerator model. Sometimes it's a challenge to tell the story because we have so much going on. But as these verticals mature, we're certainly looking to monetize and potentially spin out the most advance. So maybe that's a little bit of foreshadowing for what's to come later this year, but lots in store. Well, that would have been the predicted path as these different verticals crystallized cash flow. Spinning them out into a standalone is a good way to get your investment back. Absolutely. So exfito, it's been six weeks, eight weeks since you and I talked. Let's do this again in July. Absolutely. I'd love to Peter. Thanks a lot.